March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Development and Validation of Prediction Models for Advanced Macular Degeneration: 2006-2011
Author Affiliations & Notes
  • Johanna M. Seddon
    Ophthalmology, Tufts Univ School of Medicine, Boston, Massachusetts
    Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center, Boston, Massachusetts
  • Robyn Reynolds
    Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center, Boston, Massachusetts
  • Kimberly Chin
    Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center, Boston, Massachusetts
  • Yi Yu
    Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center, Boston, Massachusetts
  • Bernard Rosner
    Channing Laboratory, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Johanna M. Seddon, Tufts Medical Center (P); Robyn Reynolds, None; Kimberly Chin, None; Yi Yu, None; Bernard Rosner, None
  • Footnotes
    Support  RO1-EY11309 NEI/NIH;Massachusetts Lions Eye Research Fund Inc;Research to Prevent Blindness
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3321. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Johanna M. Seddon, Robyn Reynolds, Kimberly Chin, Yi Yu, Bernard Rosner; Development and Validation of Prediction Models for Advanced Macular Degeneration: 2006-2011. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3321.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Age-related macular degeneration (AMD) is a complex disease. Smoking, higher body mass index (BMI), and unhealthy diet and lifestyle increase risk. Genes also influence susceptibility. We developed several prediction models incorporating these variables: 5 loci in 3 gene regions,1 genetic and environmental factors,2 genes and environment in prospective models,3 plasma complement markers,4 6 genetic variants,5 and baseline macular drusen characteristics, genes and environment in time varying analyses to predict progression.6 To further evaluate these derived models, we performed validation analyses in another large cohort of patients.

Methods: : Models were derived from 2,914 individuals in AREDS as previously described.2,3,5,6 An independent longitudinal sample of 1,242 patients with no AMD, early or intermediate AMD, or unilateral advanced AMD at baseline was selected from ongoing genetic-epidemiologic studies of AMD for the validation sample. The average follow-up time in the validation sample was 6 years with 731 individuals followed for 5 years and 475 followed for 10 years. Variables in the models were age, sex, education, smoking, BMI, 6 genetic variants related to AMD, macular drusen phenotypes, and AMD grades for both eyes at baseline.

Results: : Discrimination of the models was excellent in the validation subset with C statistics of 0.765 and 0.812 for 5 year and 10 year progression, respectively. The model is useful for ranking and identifying high risk subjects within an external population. Knowledge of genetic susceptibility factors can distinguish low, medium and high risk groups for specific macular phenotypes.

Conclusions: : The derived models were validated and performed well in an independent sample of patients with the same range of macular pathology. Our algorithms could be useful for identifying high risk individuals for clinical trials.

Keywords: age-related macular degeneration • genetics • clinical (human) or epidemiologic studies: risk factor assessment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×